AMANDA RUTHERFORD: Open Payments
NPI 1518100908 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,869 in 142 payments from 23 companies in 2025. Trend: 2023 $800 · 2024 $2,842 · 2025 $2,869
Food & beverage: $2,869
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 19 | $539 |
| Novartis Pharmaceuticals Corporation | 14 | $253 |
| ABBVIE INC. | 16 | $235 |
| EMD Serono, Inc. | 8 | $211 |
| Neurelis, Inc. | 5 | $202 |
| SK Life Science, Inc. | 7 | $183 |
| Genentech USA, Inc. | 9 | $178 |
| ARGENX US, INC. | 7 | $155 |
| Neurocrine BioSciences, Inc. | 19 | $147 |
| Biogen, Inc. | 6 | $137 |
Products named: KESIMPTA, Briviact, VALTOCO, Nayzilam, Ocrevus Zunovo, QULIPTA, VYVGART HYTRULO, INGREZZA.
Industry payments across LA — which companies pay providers there.
